Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug.
In an interview with Endpoints News on Tuesday, Sibold touted the tolerability of Madrigal’s approved MASH …
Arena BioWorks, one of Boston’s boldest startup experiments that sought to change how science is done and how medicines are made, has shut down, a
When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at “most favored nation” prices, my mind immediately turned to
Metsera has now received new takeover bids from both Pfizer and Novo Nordisk, and has plumped for a sweetened $10bn offer from the latter.
Plus, news about Kaigene, Celltrion, Solid Bio, Terns Pharmaceuticals, Benitec, Pacira, AmacaThera, UCB, Basilea Pharmaceutica, Pfizer, Kura Oncology, Kyowa Kirin, Novavax, Sanofi, Syndexis and Relmada:
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in
Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug.
In an interview with Endpoints News on Tuesday, Sibold touted the tolerability of Madrigal’s approved MASH …